Sera Prognostics Expected To Be Added To Russell 2000 And 3000 Indexes As Part Of The Russell Indexes Annual Reconstitution

5/28/24 8:37:38 AM ET

Medical Specialities

Health Care

Get the next $SERA alert in real time by email

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution.

Get the next $SERA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SERA

Date	Price Target	Rating	Analyst
3/30/2022	$18.00 → $4.00	Buy → Neutral	Citigroup
11/19/2021	$19.00	Outperform	Oppenheimer
10/15/2021		Outperform	Cowen
8/9/2021		Outperform	William Blair
8/9/2021		Outperform	Cowen
8/9/2021	$18.00	Buy	Citigroup

More analyst ratings

$SERA
Press Releases

Fastest customizable press release news feed in the world

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025
SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
3/11/25 8:30:00 AM ET
$SERA
Medical Specialities
Health Care
Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference
SALT LAKE CITY, Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements. A live webcast of the company's presentation
2/21/25 8:30:00 AM ET
$SERA
Medical Specialities
Health Care
Sera Prognostics Announces Pricing of $50 Million Public Offering
SALT LAKE CITY, Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (NASDAQ:SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its Class A common stock at a public offering price of $3.9999 per pre-funded warrant, which equals the public offering price per share of the Class A common
2/10/25 10:41:00 PM ET
$SERA
Medical Specialities
Health Care

$SERA
Leadership Updates

Live Leadership Updates

Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO
SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the
5/15/23 5:15:00 PM ET
$SERA
Medical Specialities
Health Care
SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD
- Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies - SALT LAKE CITY, April 12, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Jane F. Barlow has joined the Sera Board of Directors. "We are very excited to have Dr. Jane Barlow join Sera's talented board," said Gregory C. Critchfield, CEO and Chairman of Sera Prognos
4/12/22 8:30:00 AM ET
$SERA
Medical Specialities
Health Care
Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board
SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Sandra A. J. Lawrence has joined the Sera Board of Directors. "We are very excited to have Sandra Lawrence join the Sera board," said Gregory C. Critchfield, CEO and Chairman of Sera Prognostics. "Sandra brings to Sera her broad and profound leadership experience having served on multiple public and private boards across
11/30/21 8:00:00 AM ET
$SERA
Medical Specialities
Health Care

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025
SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
3/11/25 8:30:00 AM ET
$SERA
Medical Specialities
Health Care
Sera Prognostics to Host Virtual R&D Day on January 31
Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY, Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. This date was changed from the prior planned date of the event due to scheduling conflicts. During the event, Sera's man
1/27/25 5:02:00 PM ET
$SERA
Medical Specialities
Health Care
SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locked in September and now seeking publication of results in connection wit
11/6/24 4:05:00 PM ET
$SERA
Medical Specialities
Health Care

Sera Prognostics Expected To Be Added To Russell 2000 And 3000 Indexes As Part Of The Russell Indexes Annual Reconstitution

Chat with this insight

Recent Analyst Ratings for
$SERA

$SERA
Press Releases

Fastest customizable press release news feed in the world

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025

Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference

Sera Prognostics Announces Pricing of $50 Million Public Offering

$SERA
Leadership Updates

Live Leadership Updates

Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD

Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board

$SERA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Information Officer Harrison Robert Gardner sold $16,116 worth of shares (3,874 units at $4.16), decreasing direct ownership by 3% to 121,757 units (SEC Form 4)

Chief Executive Officer Lindgardt Zhenya was granted 126,920 shares and sold $122,455 worth of shares (29,722 units at $4.12), increasing direct ownership by 12% to 876,657 units (SEC Form 4)

Chief Financial Officer Aerts Austin sold $19,850 worth of shares (4,818 units at $4.12), decreasing direct ownership by 2% to 309,702 units (SEC Form 4)

$SERA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

SEC Form SC 13G filed by Sera Prognostics Inc.

$SERA
SEC Filings

SEC Form 144 filed by Sera Prognostics Inc.

SEC Form 144 filed by Sera Prognostics Inc.

SEC Form SCHEDULE 13D filed by Sera Prognostics Inc.

$SERA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Sera Prognostics downgraded by Citigroup with a new price target

Oppenheimer initiated coverage on Sera Prognostics with a new price target

Cowen resumed coverage on Sera Prognostics

$SERA
Financials

Live finance-specific insights

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025

Sera Prognostics to Host Virtual R&D Day on January 31

SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics Expected To Be Added To Russell 2000 And 3000 Indexes As Part Of The Russell Indexes Annual Reconstitution

Chat with this insight

Recent Analyst Ratings for $SERA

$SERA Press Releases

Fastest customizable press release news feed in the world

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025

Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference

Sera Prognostics Announces Pricing of $50 Million Public Offering

$SERA Leadership Updates

Live Leadership Updates

Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD

Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board

$SERA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Information Officer Harrison Robert Gardner sold $16,116 worth of shares (3,874 units at $4.16), decreasing direct ownership by 3% to 121,757 units (SEC Form 4)

Chief Executive Officer Lindgardt Zhenya was granted 126,920 shares and sold $122,455 worth of shares (29,722 units at $4.12), increasing direct ownership by 12% to 876,657 units (SEC Form 4)

Chief Financial Officer Aerts Austin sold $19,850 worth of shares (4,818 units at $4.12), decreasing direct ownership by 2% to 309,702 units (SEC Form 4)

$SERA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

SEC Form SC 13G filed by Sera Prognostics Inc.

$SERA SEC Filings

SEC Form 144 filed by Sera Prognostics Inc.

SEC Form 144 filed by Sera Prognostics Inc.

SEC Form SCHEDULE 13D filed by Sera Prognostics Inc.

$SERA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Sera Prognostics downgraded by Citigroup with a new price target

Oppenheimer initiated coverage on Sera Prognostics with a new price target

Cowen resumed coverage on Sera Prognostics

$SERA Financials

Live finance-specific insights

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025

Sera Prognostics to Host Virtual R&D Day on January 31

SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Recent Analyst Ratings for
$SERA

$SERA
Press Releases

$SERA
Leadership Updates

$SERA
Insider Trading

$SERA
Large Ownership Changes

$SERA
SEC Filings

$SERA
Analyst Ratings

$SERA
Financials